ClinicalTrials.Veeva

Menu

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Hengrui Medicine logo

Hengrui Medicine

Status and phase

Terminated
Phase 3

Conditions

Metastatic Pancreatic Cancer

Treatments

Drug: Fluzoparib
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04300114
SHR3162-III-304

Details and patient eligibility

About

The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose disease has not progressed on first line platinum based chemotherapy.

Enrollment

5 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Aged ≥ 18 years.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • Expected survival ≥ 3 months.
  • Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
  • Patients who have received a minimum of 16 weeks of continuous platinum treatment for metastatic disease and have no evidence of progression based on investigator's opinion.
  • Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT or MRI.
  • Documented mutation in germline BRCA1/2 or PALB2 that is predicted to be deleterious or suspected deleterious.
  • Adequate organ performance based on laboratory blood tests.
  • Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation.
  • Ability to understand and the willingness to sign a written informed consent document.

Major Exclusion Criteria:

  • Previous treatment with a poly ADP-ribose polymerase (PARP) inhibitor.
  • Patients who have had radiotherapy within 2 weeks or participated in another clinical trial with any investigational agents within 2 weeks prior to study screening.
  • Previous treatment using CYP3A4 inducers within 3 weeks or inhibitors within 2 weeks.
  • Significant cardiovascular disease such as New York Heart Associate Class III/IV, cardiac failure, myocardial infarction, unstable arrhythmia, or evidence of ischemia on ECG within 6 months prior to enrolment.
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
  • Patients with myelodysplastic syndrome/acute myeloid leukaemia.
  • Known active hepatitis B or C infection.
  • History of immunodeficiency (including HIV infection) or organ transplantation.
  • Other serious accompanying illnesses, which, in the researcher's opinion, could seriously adversely affect the safety of the treatment.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

5 participants in 2 patient groups, including a placebo group

Maintenance Fluzoparib monotherapy
Experimental group
Treatment:
Drug: Fluzoparib
Maintenance placebo monotherapy
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

23

Loading...

Central trial contact

Chunlei Jin, Ph.D

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems